ClinicalTrials.gg
CompletedNCT05481749NEUROPSIC-GRUpdated Oct 27, 2026

Neuropsychological Assessment Of The Oldest-Old Population.(NEUROPSIC-GR)

An observational study in Dementia and Cognition Disorders in Old Age, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Completed at 6 sites in Spain. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Observational

How we know

Updated Oct 27, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
113
Ages
80 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Dementia with a site in Spain — 27 open to participants now, 37 under way, 9 of them phase 3. Dementia · Spain.

Enrollment
18th of 19
113 · median 327
Started
2023
with 9 others
Observational
19 of 114
6 open now
Registered
75th of 114
by date

Among the 114 studies in Dementia with a site in Spain, this one is the 18th largest by enrollment of the 19 observational ones that give a count, is one of 10 that started in 2023, is one of 19 observational ones, and was the 75th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

27 of the 114 studies in Dementia with a site in Spain are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 80 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Dementia with a site in Spain, or all of them as a file.
02

Study summary

Neuropsychological tests currently considered to evaluate the cognitive performance of the oldest-old population (more than 80 years) are not adapted to this group population. This trial aims to determine the normal limits for this group population of a set of 18 neuropsychological test. Results may improve the diagnostic cognitive evaluation of this population.

Read the detailed description

120 subjects more than 80y old (non-institutionalized) grouped in 4 age categories (80-84, 85-89, 90-94, 95 or more) will be evaluated through 18 neuropsychological tests (usually considered at Memory Clinics).

Subjects will be recruited from 5 Primary Care Centers by a random selection method (stratified by age group).

Normal limits will be defined by the percentiles of test punctuation. Previously, punctuation will be adjusted by age and education level by lineal regression.

03

Conditions studied

  • Dementia
  • Cognition Disorders in Old Age

Browse trials for

Keywords

  • Geriatric Assessment
  • Aged, 80 and over
  • Dementia
  • Cognition Disorders in Old Age
04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

80 or more years old non-institutionalized residents at Comarca del Garraf, a spanish region located at Barcelona Province, with a total of 112 195 people aged 80 years or more registered at public health system.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 80 or more years old
  • Residence at Comarca del Garraf
  • Able to be transfered to study center
  • Sufficient reading and writing capacity to carry out the neuropsychological tests, at the evaluator's discretion.

Exclusion criteria

Exclusion Criteria:

  • Patient at end-of-life situation or with a very short (days-weeks).
  • Hospital admission in the previous 3 months.
  • History of relevant mental illness: major depression, psychosis, bipolar disorder, obsessive-compulsive disorder.
  • Disease of the central nervous system with possible cognitive impairment: Parkinson's disease, multiple sclerosis, brain tumor, stroke with cognitive impairment, epilepsy, severe traumatic brain injury.
  • History of alcoholism or substance abuse.
  • Severe sensory deficit that prevents performing neuropsychological tests, at the discretion of the evaluator.
  • Positive Shortened Spanish Informant Questionnaire for Cognitive Decline in the Elderly questionnaire (SS-IQCODE) or Lobo's Cognitive Mini-examination Test (spanish adaptation of Minimental of Folstein test) with a score \< 23 (20 in people with low schooling or illiteracy).
  • Dementia criteria according to the IV.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
113 participants (actual)
Patient registry
No

Groups and cohorts

  • Neuropsico-Ger

    People aged 80 or more years, non-institutionalized, and without pathologies potentially affecting cognitive status.

06

What researchers measure

Primary outcomes

  1. Cognitive Performance

    Cognitive performance will be evaluated by 18 neuropsychological test (quantitative scores) which cover all main cognitive domains (memory and learning, language, perceptual-motor abilities, executive functions and attention).

    Time frame: This outcome will be evaluated at Memory Clinic Unit, following the enrollment visit. The evaluation of this outcome will last approximately 60 minutes.

07

Study locations

6 sites
  • Centro de Salud Les Roquetes-Sant Pere de Ribes
    Sant Pere de Ribes, Barcelona, Spain
  • Centros de Salud Sitges
    Sitges, Barcelona, Spain
  • Centro de Salud Vilanova i la Geltrú 1
    Vilanova i la Geltrú, Barcelona, Spain
  • Centro de Salud Vilanova i la Geltrú 2 Jaume I
    Vilanova i la Geltrú, Barcelona, Spain
  • Centro de Salud Vilanova i la Geltrú 3 Baix A Mar
    Vilanova i la Geltrú, Barcelona, Spain
  • Centro de Salud Sant Pere de Ribes
    Sant Pere de Ribes, Barcelone 08810, Spain
08

References and documents

Publications

  • Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014 Aug;30(3):421-42. doi: 10.1016/j.cger.2014.04.001. Epub 2014 Jun 12. PubMed 25037289 ↗
  • Slavin MJ, Brodaty H, Sachdev PS. Challenges of diagnosing dementia in the oldest old population. J Gerontol A Biol Sci Med Sci. 2013 Sep;68(9):1103-11. doi: 10.1093/gerona/glt051. Epub 2013 May 17. PubMed 23685769 ↗
  • Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010 Jan;67(1):114-21. doi: 10.1002/ana.21915. PubMed 20186856 ↗
  • Helmer C, Peres K, Letenneur L, Guttierez-Robledo LM, Ramaroson H, Barberger-Gateau P, Fabrigoule C, Orgogozo JM, Dartigues JF. Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity. Dement Geriatr Cogn Disord. 2006;22(1):87-94. doi: 10.1159/000093459. Epub 2006 May 18. PubMed 16710088 ↗
  • Pena-Casanova J, Blesa R, Aguilar M, Gramunt-Fombuena N, Gomez-Anson B, Oliva R, Molinuevo JL, Robles A, Barquero MS, Antunez C, Martinez-Parra C, Frank-Garcia A, Fernandez M, Alfonso V, Sol JM; NEURONORMA Study Team. Spanish Multicenter Normative Studies (NEURONORMA Project): methods and sample characteristics. Arch Clin Neuropsychol. 2009 Jun;24(4):307-19. doi: 10.1093/arclin/acp027. Epub 2009 Jun 23. PubMed 19549723 ↗
  • Bonete Lopez B, Oltra-Cucarella J, Lorente Martinez R, Sitges Macia E. [Normative data of the abbreviated-revised Barcelona test for cognitively active elderly people]. Rev Esp Geriatr Gerontol. 2020 May-Jun;55(3):137-146. doi: 10.1016/j.regg.2019.09.007. Epub 2019 Dec 23. Spanish. PubMed 31874774 ↗
  • Guardia-Olmos J, Pero-Cebollero M, Rivera D, Arango-Lasprilla JC. Methodology for the development of normative data for ten Spanish-language neuropsychological tests in eleven Latin American countries. NeuroRehabilitation. 2015;37(4):493-9. doi: 10.3233/NRE-151277. PubMed 26577889 ↗
  • Giulioli C, Meillon C, Gonzalez-Colaco Harmand M, Dartigues JF, Amieva H. Normative Scores for Standard Neuropsychological Tests in the Oldest Old From the French Population-Based PAQUID Study. Arch Clin Neuropsychol. 2016 Feb;31(1):58-65. doi: 10.1093/arclin/acv055. Epub 2015 Sep 8. PubMed 26353935 ↗
  • Beker N, Sikkes SAM, Hulsman M, Schmand B, Scheltens P, Holstege H. Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100-Plus Study. J Am Geriatr Soc. 2019 Apr;67(4):759-767. doi: 10.1111/jgs.15729. Epub 2018 Dec 27. PubMed 30592018 ↗
  • Whittle C, Corrada MM, Dick M, Ziegler R, Kahle-Wrobleski K, Paganini-Hill A, Kawas C. Neuropsychological data in nondemented oldest old: the 90+ Study. J Clin Exp Neuropsychol. 2007 Apr;29(3):290-9. doi: 10.1080/13803390600678038. PubMed 17454349 ↗
  • Weeks A, Swerissen H, Belfrage J. Issues, challenges, and solutions in translating study instruments. Eval Rev. 2007 Apr;31(2):153-65. doi: 10.1177/0193841X06294184. PubMed 17356181 ↗
  • del Ser Quijano T, Garcia de Yebenes MJ, Sanchez Sanchez F, Frades Payo B, Rodriguez Laso A, Bartolome Martinez MP, Otero Puime A. [Cognitive assessment in the elderly. Normative data of a Spanish population sample older than 70 years]. Med Clin (Barc). 2004 May 22;122(19):727-40. doi: 10.1157/13062190. Spanish. PubMed 15171906 ↗
  • Morales JM, Gonzalez-Montalvo JI, Bermejo F, Del-Ser T. The screening of mild dementia with a shortened Spanish version of the "Informant Questionnaire on Cognitive Decline in the Elderly". Alzheimer Dis Assoc Disord. 1995 Summer;9(2):105-11. doi: 10.1097/00002093-199509020-00008. PubMed 7662322 ↗
  • Lobo A, Ezquerra J, Gomez Burgada F, Sala JM, Seva Diaz A. [Cognocitive mini-test (a simple practical test to detect intellectual changes in medical patients)]. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1979 May-Jun;7(3):189-202. No abstract available. Spanish. PubMed 474231 ↗
  • Miranda JP, Valencia RR. English and Spanish Versions of a Memory Test: Word-Length Effects Versus Spoken-Duration Effects. Hispanic Journal of Behavioral Sciences. 1997 May 1;19(2):171-81
  • Osterrieth PA. Le test de copie d'une figure complexe; contribution à l'étude de la perception et de la mémoire. [Test of copying a complex figure; contribution to the study of perception and memory.]. Archives de Psychologie. 1944;30:206-356
  • Rey A. L'examen psychologique dans les cas d'encéphalopathie traumatique. (Les problems.). [The psychological examination in cases of traumatic encepholopathy. Problems.]. Archives de Psychologie. 1941;28:215-85
  • Ortega G, Alegret M, Espinosa A, Ibarria M, Cañabate P, Boada M. Valoración de las funciones viso-perceptivas y viso-espaciales en la práctica forense. Rev Esp Med Legal. 2014 Apr 1;40(2):83-5
  • Della Sala S, Laiacona M, Spinnler H, Trivelli C. Poppelreuter-Ghent's Overlapping Figures Test: its sensitivity to age, and its clinical use. Arch Clin Neuropsychol. 1995 Nov;10(6):511-34. doi: 10.1016/0887-6177(94)00049-v. PubMed 14588906 ↗
  • Weiner MF, Hynan LS, Rossetti H, Falkowski J. Luria's three-step test: what is it and what does it tell us? Int Psychogeriatr. 2011 Dec;23(10):1602-6. doi: 10.1017/S1041610211000767. Epub 2011 May 4. PubMed 21554794 ↗
  • Quinones-Ubeda S, Pena-Casanova J, Bohm P, Gramunt-Fombuena N, Comas L. [Preliminary normative data for the second edition of the Boston Naming Test for young Spanish adults]. Neurologia. 2004 Jun;19(5):248-53. Spanish. PubMed 15150707 ↗
  • Ramier AM, Hecaen H. [Respective roles of frontal lesions and lesion lateralization in "verbal fluency" deficiencies]. Rev Neurol (Paris). 1970 Jul;123(1):17-22. No abstract available. French. PubMed 5516326 ↗
  • Ramirez M, Ostrosky-Solis F, Fernandez A, Ardila-Ardila A. [Semantic verbal fluency in Spanish-speaking people: a comparative analysis]. Rev Neurol. 2005 Oct 16-31;41(8):463-8. Spanish. PubMed 16224732 ↗
  • Brown RR, Partington JE. Short Articles and Notes: The Intelligence of the Narcotic Drug Addict. The Journal of General Psychology. 1942 Jan 1;26(1):175-9.
  • Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000 Dec 12;55(11):1621-6. doi: 10.1212/wnl.55.11.1621. PubMed 11113214 ↗
  • Hurtado-Pomares M, Valera-Gran D, Sanchez-Perez A, Peral-Gomez P, Navarrete-Munoz EM, Terol-Cantero MC. Adaptation of the Spanish version of the Frontal Assessment Battery for detection of executive dysfunction. Med Clin (Barc). 2021 Mar 12;156(5):229-232. doi: 10.1016/j.medcli.2020.04.028. Epub 2020 Sep 9. English, Spanish. PubMed 32919777 ↗
  • Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology. 1935;18(6):643-62
  • Hobson P, Meara J, Taylor C. The Weigl Colour-Form Sorting Test: a quick and easily administered bedside screen for dementia and executive dysfunction. Int J Geriatr Psychiatry. 2007 Sep;22(9):909-15. doi: 10.1002/gps.1765. PubMed 17245801 ↗
  • Martí D, Miralles R, Llorach I, García-Palleiro P, Esperanza A, Guillem J, et al. Trastornos depresivos en una unidad de convalecencia: experiencia y validación de una versión española de 15 preguntas de la escala de depresión geriátrica de Yesavage. Rev Esp Geriatr Gerontol. 2000 Jan 1;35(1):7-14
  • MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965 Feb;14:61-5. No abstract available. PubMed 14258950 ↗
  • Baztán JJ, Pérez Del Molino J, Alarcón T, San Cristóbal E, Izquierdo G, Manzarbeitia I. Índice de Barthel: Instrumento válido para la valoración funcional de pacientes con enfermedad cerebrovascular. Rev Esp Geriatr Gerontol. 1993;28:32-40.
  • Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 Autumn;9(3):179-86. No abstract available. PubMed 5349366 ↗
  • Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, et al. Mayo's Older Americans Normative Studies: WAIS-R norms for ages 56 to 97. Clinical Neuropsychologist. 1992;6(Suppl):1-30.
  • Lucas JA, Ivnik RJ, Willis FB, Ferman TJ, Smith GE, Parfitt FC, Petersen RC, Graff-Radford NR. Mayo's Older African Americans Normative Studies: normative data for commonly used clinical neuropsychological measures. Clin Neuropsychol. 2005 Jun;19(2):162-83. doi: 10.1080/13854040590945265. PubMed 16019702 ↗
  • Pauker JD. Constructing overlapping cell tables to maximize the clinical usefulness of normative test data: rationale and an example from neuropsychology. J Clin Psychol. 1988 Nov;44(6):930-3. doi: 10.1002/1097-4679(198811)44:63.0.co;2-h. PubMed 3216017 ↗
  • Mungas D, Marshall SC, Weldon M, Haan M, Reed BR. Age and education correction of Mini-Mental State Examination for English and Spanish-speaking elderly. Neurology. 1996 Mar;46(3):700-6. doi: 10.1212/wnl.46.3.700. PubMed 8618670 ↗
  • Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9. PubMed 31078660 ↗
  • World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053. No abstract available. PubMed 24141714 ↗

Individual participant data

Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research proposels and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication of main results of the study.

Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2023 to primary completion in Jan 2026, 35 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Mar 2026 → Jan 2026 and completion Mar 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Aug 1, 2022
StartActual
Feb 14, 2023
Primary completionActual
Jan 29, 2026was Mar 2026
CompletionActual
Jan 29, 2026was Mar 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 27, 2026
Primary completion
Mar 2026→Jan 29, 2026 (actual)
Oct 27, 2026
Study completion
Mar 2026→Jan 29, 2026 (actual)
Oct 27, 2026
Enrollment
120 (estimated)→113 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Completed
    Primary completion Mar 2026→Jan 29, 2026 (now actual)
    Study completion Mar 2026→Jan 29, 2026 (now actual)
    Enrollment 120 (estimated)→113 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05481749
Lead sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Collaborators
Centro de Salud Vilanova i la Geltrú 2 Jaume I, Barcelona, Spain, Centro de Salud Vilanova i la Geltrú 3 Baix A Mar, Barcelona, Spain, Centro de Salud Les Roquetes-Sant Pere de Ribes, Barcelona, Spain, Gerència Territorial Metropolitana Sud, Alt Penedès i Garraf, Barcelona, Spain, Centro de Salud Sant Pere de Ribes, Barcelona, Spain, Centro de Salud Vilanova i la Geltrú 1 Sant Joan, Barcelona, Spain, Centro de Salud Sitges, Barcelona, Spain
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Feb 14, 2023
Primary completion
Jan 29, 2026
Completion
Jan 29, 2026
Last update
Oct 27, 2026

Study contacts

César Gálvez-Barrón, Ph.D.
principal investigator · Consorci Sanitari de l'Alt Penedès i Garraf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion